共 33 条
[1]
Chung H(2010)Changing trends in hepatitis C infection over the past 50 years in Japan Intervirology 53 39-43
[2]
Ueda T(2013)C virus infection: first edition, May 2012, the Japan Society of Hepatology Hepatol Res. 43 1-34
[3]
Kudo M(2014)Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1-infected patients in Japan: the DRAGON study J Gastroenterol 49 138-147
[4]
Hayashi N(2010)Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor J Med Chem 53 2443-2463
[5]
Seto C(2011)Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents Antimicrob Agents Chemother 55 937-939
[6]
Kato M(2010)MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob Agents Chemother 54 305-311
[7]
McCauley JA(2013)Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics Antiviral Res 99 214-220
[8]
McIntyre CJ(2012)Vaniprevir with peginterferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C: a randomized phase 2 study Hepatology 56 884-893
[9]
Rudd MT(2014)Combination of vaniprevir with peginterferon and ribavirin significantly increases the rate of sustained viral response in treatment-experienced patients with chronic HCV genotype 1 infection and cirrhosis Clin Gastroenterol Hepatol. 12 1029-1037
[10]
Olsen DB(1985)Comparative analysis of two rates Stat Med 4 213-226